Welcome to our dedicated page for Cellectar Biosciences SEC filings (Ticker: CLRB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cellectar Biosciences, Inc. (NASDAQ: CLRB) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including registration statements, current reports and other documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into Cellectar’s late-stage clinical oncology programs, capital structure and risk factors.
Through forms such as Form S‑1 and S‑1/A, investors can review descriptions of the company’s Phospholipid Drug Conjugate (PDC) platform, its lead radiotherapeutic candidates iopofosine I 131, CLR 121125 (CLR 125) and CLR 121225 (CLR 225), and the clinical and preclinical data supporting these programs. These registration statements also outline unit offerings, warrant terms, use of proceeds and the impact of actions like the one‑for‑thirty reverse stock split.
Form 8‑K current reports document material events, including scientific advice from the European Medicines Agency’s Scientific Advice Working Party on a potential Conditional Marketing Authorization for iopofosine I 131 in Waldenstrom’s macroglobulinemia, warrant inducement transactions, reverse stock split implementation, and preliminary financial information. Earnings press releases furnished as exhibits to 8‑Ks provide narrative overviews of quarterly performance and corporate updates.
On Stock Titan, CLRB filings are supplemented with AI‑generated highlights that summarize key points from lengthy documents, helping users quickly identify information on clinical milestones, regulatory designations, financing transactions and changes to capital structure. Real‑time updates from EDGAR ensure that new Cellectar filings, including future 10‑K annual reports, 10‑Q quarterly reports and any Form 4 insider transaction disclosures, are incorporated as they become available, while the full text remains accessible for detailed review.
Cellectar Biosciences entered into warrant exercise inducement letters with certain holders who agreed to exercise existing warrants covering 1,048,094 common shares at an exercise price of $5.25 per share and to pay $0.125 per new warrant. In return, the company issued new Series I and Series II inducement warrants. The transactions closed on October 8, 2025 and generated aggregate gross proceeds of approximately $5.8 million.
The Series I inducement warrants are immediately exercisable at $6.00 per share and expire on October 8, 2030, while the Series II inducement warrants are immediately exercisable at $6.00 per share and expire on April 8, 2027. Cellectar announced an estimated cash and cash equivalents balance of approximately $12.6 million as of September 30, 2025 and anticipates that this, together with approximately $5.2 million in net proceeds from the warrant transactions, will be sufficient to fund operations into the third quarter of 2026.
Cellectar Biosciences, Inc. disclosed a Form 8-K reporting the release of a corporate press statement and related communications. The filing identifies certain securities‑law communication categories including written communications under Rule 425 and soliciting/pre‑commencement communications under Rules 14a‑12, 14d‑2(b), and 13e‑4(c). The company also flagged its status as an emerging growth company and furnished the press release as Exhibit 99.1, with the cover page interactive data included as Exhibit 104. The document is signed by the company’s Chief Financial Officer, indicating formal disclosure and corporate authorization.
Cellectar Biosciences, Inc. Schedule 13G/A filing reports that ADAR1-related parties collectively beneficially own 2,962 shares of the issuer's common stock, representing approximately 0.1% of the 2,677,039 shares outstanding referenced from the issuer's July 2, 2025 prospectus. The holdings consist of 2,540 shares held by ADAR1 Partners, LP and 422 shares held by Spearhead Insurance Solutions IDF, LLC. ADAR1 Capital Management, its GP, and Daniel Schneeberger report indirect shared voting and dispositive power over these shares and state the securities were acquired in the ordinary course of business.
Laurence W. Lytton filed an Amendment to Schedule 13G reporting beneficial ownership of warrants to acquire 51,391 shares of Cellectar Biosciences, Inc. common stock. The filing states these warrants represent 1.6% of the outstanding common stock, calculated using 3,192,040 shares outstanding reported by the issuer for the quarter ended June 30, 2025. The reporting person indicates sole voting and dispositive power over the 51,391 underlying shares and certifies the securities were not acquired to change or influence control of the issuer.
Cellectar Biosciences, Inc. (CLRB) disclosure shows that Nantahala Capital Management, LLC and two individuals, Wilmot B. Harkey and Daniel Mack, may be deemed beneficial owners of 1,109 shares of the company’s common stock, representing 0.06% of the class. The shares are held by funds and separately managed accounts under Nantahala's control and the Reporting Persons report shared voting and dispositive power over those 1,109 shares. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control.
Cellectar Biosciences, Inc. filed a current report to note that it issued a press release on August 14, 2025 announcing its financial results for the quarter ended June 30, 2025 and providing a corporate update. The press release is furnished as Exhibit 99.1 and is incorporated by reference. The company’s common stock, par value $0.00001 per share, trades on The Nasdaq Capital Market under the symbol CLRB.
Cellectar Biosciences reports a mixed quarter: clinical progress on its lead radioconjugate and significant financial strain. Total assets declined to $13.7 million from $25.5 million, driven by a fall in cash and cash equivalents to $11.04 million from $23.29 million. The company recorded a net loss of $12.05 million for the six months and has an accumulated deficit of approximately $259.4 million. Operating expenses for the six months totaled $12.44 million, composed of research and development of $5.82 million and general and administrative of $6.62 million.
Operationally, Cellectar received Breakthrough Therapy Designation for iopofosine I-131 in relapsed/refractory Waldenstrom macroglobulinemia and reported strong CLOVER WaM results: a major response rate of 58.2% and an overall response rate of 83.6%. Development programs CLR 125 and CLR 225 are positioned for Phase 1 trials in 2025 but are explicitly conditioned on obtaining additional financing. Management discloses substantial doubt about going concern, with available liquidity near $15 million and runway described as limited absent further financing; planned actions include sales of equity/debt, strategic transactions, and cost savings. A July 2, 2025 underwritten offering raised approximately $6.9 million gross as a subsequent event.
Cellectar Biosciences, Inc. is reported to have Hexstone Capital LLC and Brendan O'Neil as joint reporting persons that beneficially own 150,000 shares of common stock, representing 5.6% of the outstanding shares used for this calculation. The percentage is calculated on a post-offering share count of 2,677,039 shares disclosed in the issuer's prospectus. Hexstone also holds 150,000 warrants exercisable for common stock, but those warrants are not included in the ownership total because they are subject to a 4.99% ownership limitation that blocks exercise if it would increase beneficial ownership above that threshold. Mr. O'Neil is the managing member of Hexstone and may be deemed to beneficially own the shares held by Hexstone; he does not directly own the shares. The filing includes a certification that the securities were not acquired to change or influence control of the issuer.